This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Hagens Berman Sobol Shapiro LLP Lawsuit: Fresenius Medical Care And DaVita Healthcare Partners Liable For GranuFlo And NaturaLyte Deaths

SEATTLE, March 6, 2013 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a law firm with experience prosecuting cases against healthcare providers and the pharmaceutical industry, today filed two lawsuits in Federal Court in Colorado alleging that DaVita Healthcare Partners, Inc.'s (NYSE: DVA) ("DaVita") actions led to the deaths of two dialysis patients. The lawsuits further allege that the problems that caused those deaths have impacted thousands of dialysis patients across the country, and seek class action status.

The suits claim that DaVita – one of the nation's largest providers of dialysis services – failed to recognize that part of the treatment it used in dialysis was causing dangerously high levels of bicarbonates in the patients, which the suit claims caused the deaths of the two patients cited in the suits, and potentially many other unreported deaths and injuries, including cardiac arrest and stroke.

Hagens Berman has also filed suits against Fresenius Medical Care North America (FMC) ("Fresenius"), the company who manufactured and distributed the two products. According to those lawsuits, an internal memo dated Nov. 4, 2011, reveals that Fresenius knew of the dangers associated with GranuFlo and NaturaLyte, two dialysis products, far in advance of informing the FDA. Moreover, the complaints allege that Fresenius made adjustments at its own clinics to reduce the impact on patients, showing it was aware of the problem.

The suits seek to represent patients who suffered cardiac arrest, stroke, respiratory issues or a litany of other health problems linked to the use of GranuFlo and NaturaLyte, both of which were recalled by the FDA on March 29, 2012.

Patients, former patients or their surviving families who believe they suffered from cardiac, stroke or other adverse events associated with the products are encouraged to contact Hagens Berman attorneys. You can reach an attorney by calling 888-381-2889 or by emailing

According to Steve Berman, managing partner of Hagens Berman, DaVita shares the blame, even though Fresenius manufactured and distributed the products. "Even before the FDA stepped in, our medical experts all conclude that DaVita should have recognized that its patients using the two products showed wild swings in their bicarbonate levels, a clear indication that they were at a much higher risk of cardiac arrest."

Berman also noted that DaVita failed to recognize trends in the number of complications and deaths after dialysis treatments. "Even had the company overlooked the trends relating to bicarbonate levels, we would expect that the high number of complications and deaths would have alerted them that something was amiss."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs